@article{d7f9452ec06c46eda8bfeddbfff42f5f,
title = "Venous Tone and Stressed Blood Volume in Heart Failure: JACC Review Topic of the Week",
abstract = "A number of pathologic processes contribute to the elevation in cardiac filling pressures in heart failure (HF), including myocardial dysfunction and primary volume overload. In this review, we discuss the important role of the venous system and the concepts of stressed blood volume and unstressed blood volume. We review how regulation of venous tone modifies the distribution of blood between these 2 functional compartments, the physical distribution of blood between the pulmonary and systemic circulations, and how these relate to the hemodynamic abnormalities observed in HF. Finally, we review recently applied methods for estimating stressed blood volume and how they are being applied to the results of clinical studies to provide new insights into resting and exercise hemodynamics and therapeutics for HF.",
keywords = "exercise, heart failure, stressed blood volume, unstressed blood volume, venous tone, volume regulation",
author = "Marat Fudim and Kaye, {David M.} and Borlaug, {Barry A.} and Shah, {Sanjiv J.} and Stuart Rich and Kapur, {Navin K.} and Costanzo, {Maria Rosa} and Brener, {Michael I.} and Kenji Sunagawa and Daniel Burkhoff",
note = "Funding Information: Dr Fudim was supported by the National Heart, Lung, and Blood Institute (NHLBI) (NHLBI K23HL151744), the American Heart Association (grant number 20IPA35310955), Mario Family Award, Duke Chair{\textquoteright}s Award, Translating Duke Health Award, Bayer, and BTG Specialty Pharmaceuticals; and has received consulting fees from AxonTherapies, Bodyport, CVRx, Daxor, Edwards LifeSciences, NXT Biomedical, Zoll, and Viscardia. Dr Borlaug has received research funding from the National Institutes of health/NHLBI (R01 HL128526, U01 HL125205), AstraZeneca, Corvia, Medtronic, Mesoblast, GlaxoSmithKline, and TENAX; and has served on the Advisory Board/as a consultant for Merck, Novartis, Lilly, and Novo Nordisk. Dr Shah has consulted for AxonTherapies. Dr Rich is the chief medical officer of Tenax. Dr Burkhoff has received institutional grants from Abiomed, Ancora, and Fire 1; and has received consulting fees from PVLoops LLC and Axon Therapeutics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2022 American College of Cardiology Foundation",
year = "2022",
month = may,
day = "10",
doi = "10.1016/j.jacc.2022.02.050",
language = "English (US)",
volume = "79",
pages = "1858--1869",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "18",
}